DE69420632T2 - Verfahren zur Herstellung von Arzneizubereitungen mit verzögerter Wirkstoffabgabe - Google Patents

Verfahren zur Herstellung von Arzneizubereitungen mit verzögerter Wirkstoffabgabe

Info

Publication number
DE69420632T2
DE69420632T2 DE69420632T DE69420632T DE69420632T2 DE 69420632 T2 DE69420632 T2 DE 69420632T2 DE 69420632 T DE69420632 T DE 69420632T DE 69420632 T DE69420632 T DE 69420632T DE 69420632 T2 DE69420632 T2 DE 69420632T2
Authority
DE
Germany
Prior art keywords
water
soluble polypeptide
preparation
active substances
pharmaceutical preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69420632T
Other languages
English (en)
Other versions
DE69420632D1 (de
Inventor
Yasutaka Igari
Kazumichi Yamamoto
Kayoko Okamoto
Yutaka Yamagata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DE69420632D1 publication Critical patent/DE69420632D1/de
Publication of DE69420632T2 publication Critical patent/DE69420632T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
DE69420632T 1993-07-05 1994-07-05 Verfahren zur Herstellung von Arzneizubereitungen mit verzögerter Wirkstoffabgabe Expired - Fee Related DE69420632T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP16579393 1993-07-05
JP8176594 1994-04-20

Publications (2)

Publication Number Publication Date
DE69420632D1 DE69420632D1 (de) 1999-10-21
DE69420632T2 true DE69420632T2 (de) 2000-03-02

Family

ID=26422772

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69420632T Expired - Fee Related DE69420632T2 (de) 1993-07-05 1994-07-05 Verfahren zur Herstellung von Arzneizubereitungen mit verzögerter Wirkstoffabgabe

Country Status (11)

Country Link
US (1) US5534269A (de)
EP (1) EP0633020B1 (de)
KR (1) KR950002748A (de)
CN (1) CN1106653A (de)
AT (1) ATE184480T1 (de)
AU (1) AU674077B2 (de)
CA (1) CA2127317C (de)
DE (1) DE69420632T2 (de)
FI (1) FI943205A (de)
NO (1) NO942515L (de)
NZ (1) NZ260909A (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004046102A1 (de) * 2004-09-23 2006-04-06 Mars Inc. Indikatorgranulat

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
EP0835101B1 (de) * 1995-06-27 2004-06-09 Takeda Chemical Industries, Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
CA2230494A1 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
CA2241322C (en) * 1996-03-28 2009-01-13 Takeda Chemical Industries, Ltd. Sustained-release preparation and its production
US6197350B1 (en) 1996-12-20 2001-03-06 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
EP1049458B1 (de) * 1998-01-21 2003-03-26 Takeda Chemical Industries, Ltd. Verfahren zur gerfriertrocknung von präparaten mit verzörgerter wirkstoffabgabe
KR20010042079A (ko) 1998-03-20 2001-05-25 다케다 야쿠힌 고교 가부시키가이샤 생리학적으로 활성인 폴리펩티드의 서방 제제 및 그것의제조 방법
FR2778847A1 (fr) * 1998-05-20 1999-11-26 Jean Pierre Perraud Implant injectable en sous gingival resorbable, constitue de microspheres a liberation prolongee et chargees en principes actifs et en suspension dans un gel vecteur
US6165509A (en) * 1998-09-01 2000-12-26 University Of Washington Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
FR2793684B1 (fr) * 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
ATE389414T1 (de) 1999-09-08 2008-04-15 Chugai Pharmaceutical Co Ltd Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben
EP1219298A4 (de) 1999-09-17 2003-06-11 Takeda Chemical Industries Ltd Verfahren zur herstellung von proteinpulver
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7998929B2 (en) * 2000-09-01 2011-08-16 Chugai Seikyaku Kabushiki Kaisha Solution preparations stabilized over long time
EP1356809A4 (de) * 2000-12-28 2008-05-14 Takeda Pharmaceutical Retardzubereitungen
PT1397155E (pt) 2001-06-21 2015-12-07 Genentech Inc Formulação de libertação sustentada
TWI225416B (en) 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
CN101444476B (zh) * 2001-12-26 2011-11-30 武田药品工业株式会社 新微球和其生产方法
US8519008B2 (en) 2003-01-22 2013-08-27 Purina Animal Nutrition Llc Method and composition for improving the health of young monogastric mammals
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
WO2005003180A2 (en) * 2003-04-10 2005-01-13 Pr Pharmaceuticals A method for the production of emulsion-based micro particles
ES2307009T3 (es) * 2003-04-15 2008-11-16 Opperbas Holding B.V. Composicion farmaceutica que contiene proteinas y/o polipeptidos y particulas coloidales.
CN102935069A (zh) * 2003-07-15 2013-02-20 Pr药品有限公司 控释组合物的制备方法
EP2444069B1 (de) * 2003-07-23 2019-06-05 Evonik Corporation Zusammensetzung mit kontrollierter Freisetzung
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CN101199623B (zh) * 2006-12-16 2011-04-27 石茂光 治疗高血压药物缓控释制剂的制备方法
HUE030789T2 (en) 2007-05-18 2017-06-28 Durect Corp Improved depot formulation
CN101801415B (zh) 2007-05-25 2015-09-23 Rb医药品有限公司 利培酮化合物的持续递送制剂
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
CN105163719B (zh) 2013-03-11 2019-03-08 度瑞公司 包含高粘度液体载体的可注射控制释放组合物
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
CN104288123B (zh) * 2014-10-27 2016-09-14 浙江理工大学 一种负载干扰素微胶囊的制备方法
CN110404115B (zh) * 2019-07-23 2022-03-18 广东省医疗器械研究所 一种具有表面坑洞的碳酸盐/可降解高分子微球及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
JP3116311B2 (ja) * 1990-06-13 2000-12-11 エーザイ株式会社 マイクロスフィアの製法
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5171579A (en) * 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
US5470582A (en) * 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004046102A1 (de) * 2004-09-23 2006-04-06 Mars Inc. Indikatorgranulat
DE102004046102B4 (de) * 2004-09-23 2009-09-03 Mars Inc. Indikatorgranulat
US7670845B2 (en) 2004-09-23 2010-03-02 Mars Incorporated Indicator granular material

Also Published As

Publication number Publication date
CA2127317C (en) 2008-10-07
ATE184480T1 (de) 1999-10-15
EP0633020A1 (de) 1995-01-11
CN1106653A (zh) 1995-08-16
AU674077B2 (en) 1996-12-05
US5534269A (en) 1996-07-09
AU6614594A (en) 1995-01-12
NO942515D0 (no) 1994-07-04
KR950002748A (ko) 1995-02-16
CA2127317A1 (en) 1995-01-06
DE69420632D1 (de) 1999-10-21
FI943205A (fi) 1995-01-06
FI943205A0 (fi) 1994-07-05
NO942515L (no) 1995-01-06
NZ260909A (en) 1995-04-27
EP0633020B1 (de) 1999-09-15

Similar Documents

Publication Publication Date Title
DE69420632D1 (de) Verfahren zur Herstellung von Arzneizubereitungen mit verzögerter Wirkstoffabgabe
ATE178616T1 (de) Verfahren zur herstellung von biologisch aktivem protein (z.b. tgf)
DE69033874D1 (de) Verfahren zur Herstellung von arzneimittelenthaltenden gefriergetrockneten Formulierungen
DE69408265D1 (de) Verfahren zur Herstellung von Polybutadien mit hochaktiven Katalysatoren
DE68919246T2 (de) Verfahren zur Herstellung von Aminosäuren.
DE69011880D1 (de) Verfahren zur Herstellung von L-Aminosäuren durch Fermentation.
DE68916754T2 (de) Verfahren zur Herstellung von optisch aktiver 3-Hydroxybuttersäure.
DE69904701D1 (de) Physiologisch aktives polypeptid enthaltende zubereitung mit verzögerter freisetzung und deren herstellung
DE69009237T2 (de) Verfahren zur Herstellung von optisch aktiven Estern der 6-t-Butoxy-3,5-dihydroxyhexansäure.
DE58907182D1 (de) Verfahren zur Herstellung von 6-Aminocapronsäureestern.
DE68924011T2 (de) Verfahren zur Herstellung von Pyrazolkarbonsäure und Derivaten.
DE68915310T2 (de) Verfahren zur Herstellung von enantiomerischen homogenen Aminopyrrolidinyl-naphthyridin- und Quinoloncarbonsäuren.
DE59004490D1 (de) Verfahren zur Herstellung von alpha-Fluoracrylsäurederivaten.
DE3871410D1 (de) (phenylethenyl)phenylpropionaldehyd und verfahren zur herstellung von (benzoylphenyl)propionsaeure unter verwendung dieser verbindung.
DE68913342D1 (de) Verfahren zur Herstellung von Carbonsäureestern.
DE68909305D1 (de) Verfahren zur Herstellung von Carbonsäureestern.
DE69013621D1 (de) Verfahren zur Herstellung von tertiärem Amino-Alkohol.
DE58908961D1 (de) Verfahren zur Isolierung von 2-Keto-polyhydroxy-C6-carbonsäuren, insbesondere von 2-Keto-L-gulonsäure aus wässrigen Fermentationsausträgen.
DE69002568D1 (de) Verfahren zur herstellung von optisch aktiven 2-arylpropionsaeuren.
DE58909208D1 (de) Verfahren zur Herstellung von Imidazol-2-carbonsäuren.
DE3878560T2 (de) Verfahren zur herstellung von estern n-substituierter aminosaeuren.
DE68928788D1 (de) Verfahren zur Herstellung von optisch aktiven 3,4-Dihydroxybuttersäurederivaten
ATE94766T1 (de) Verfahren zur herstellung einer galenischen zubereitung mit optimaler bioverfuegbarkeit des wirkstoffs 2-hydroxy-5-methyllaurophenonoxime (hmlo).
DE68915893T2 (de) Verfahren zur Herstellung von aliphatischen Karbonsäuren.
DE58907865D1 (de) Verfahren zur Herstellung von alpha-Ketocarbonsäureestern.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: TAKEDA PHARMACEUTICAL CO. LTD., OSAKA, JP

8339 Ceased/non-payment of the annual fee